ZA200505777B - New strains of bifidobacterium having the ability to produce glutamine - Google Patents

New strains of bifidobacterium having the ability to produce glutamine Download PDF

Info

Publication number: ZA200505777B
Authority: ZA; South Africa
Prior art keywords: cure; bifidobacterium; strains; dsm; strain
Prior art date: 2003-01-31

Application number

ZA200505777A

Other languages

English (en)

Inventor

Molin Goran

Ahrnu Siv

Jeppsson Bengt

Original Assignee

Probi Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-31

Filing date

2004-01-27

Publication date

2007-12-27

2004-01-27 Application filed by Probi Ab filed Critical Probi Ab

2007-12-27 Publication of ZA200505777B publication Critical patent/ZA200505777B/en

Links

ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims abstract description 50
241000186000 Bifidobacterium Species 0.000 title claims abstract description 48
241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 60
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 26
239000004475 Arginine Substances 0.000 claims abstract description 25
239000000203 mixture Substances 0.000 claims abstract description 19
210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 13
238000001727 in vivo Methods 0.000 claims abstract description 7
238000001356 surgical procedure Methods 0.000 claims abstract description 7
238000002512 chemotherapy Methods 0.000 claims abstract description 6
230000002980 postoperative effect Effects 0.000 claims abstract description 5
238000011282 treatment Methods 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims abstract description 4
230000008383 multiple organ dysfunction Effects 0.000 claims abstract description 4
238000002360 preparation method Methods 0.000 claims abstract description 4
208000037112 Intestinal Failure Diseases 0.000 claims abstract description 3
208000027866 inflammatory disease Diseases 0.000 claims abstract description 3
238000011321 prophylaxis Methods 0.000 claims abstract description 3
238000002560 therapeutic procedure Methods 0.000 claims abstract description 3
229940004120 bifidobacterium infantis Drugs 0.000 claims description 37
239000012634 fragment Substances 0.000 claims description 28
108020004465 16S ribosomal RNA Proteins 0.000 claims description 17
238000009396 hybridization Methods 0.000 claims description 16
108090000623 proteins and genes Proteins 0.000 claims description 16
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 15
239000013611 chromosomal DNA Substances 0.000 claims description 13
239000000523 sample Substances 0.000 claims description 10
241000186660 Lactobacillus Species 0.000 claims description 9
241000588724 Escherichia coli Species 0.000 claims description 8
238000002105 Southern blotting Methods 0.000 claims description 8
229940039696 lactobacillus Drugs 0.000 claims description 8
244000199866 Lactobacillus casei Species 0.000 claims description 7
238000000246 agarose gel electrophoresis Methods 0.000 claims description 7
229910021529 ammonia Inorganic materials 0.000 claims description 7
238000000926 separation method Methods 0.000 claims description 7
235000013325 dietary fiber Nutrition 0.000 claims description 4
235000013305 food Nutrition 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 45
206010009887 colitis Diseases 0.000 abstract description 16
230000001580 bacterial effect Effects 0.000 abstract description 9
241000700159 Rattus Species 0.000 abstract description 7
230000003247 decreasing effect Effects 0.000 abstract description 7
230000000694 effects Effects 0.000 abstract description 7
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 5
241000186606 Lactobacillus gasseri Species 0.000 abstract description 5
210000000936 intestine Anatomy 0.000 abstract description 5
230000008092 positive effect Effects 0.000 abstract description 5
238000005070 sampling Methods 0.000 abstract description 5
230000005945 translocation Effects 0.000 abstract description 5
241000186605 Lactobacillus paracasei Species 0.000 abstract description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
206010070545 Bacterial translocation Diseases 0.000 abstract description 3
230000007375 bacterial translocation Effects 0.000 abstract description 3
230000009266 disease activity Effects 0.000 abstract description 3
230000006698 induction Effects 0.000 abstract description 2
229920003045 dextran sodium sulfate Polymers 0.000 abstract 3
241000700157 Rattus norvegicus Species 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002443 hepatoprotective effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
235000004554 glutamine Nutrition 0.000 description 44
229960002743 glutamine Drugs 0.000 description 44
238000012360 testing method Methods 0.000 description 20
235000010633 broth Nutrition 0.000 description 18
229920001817 Agar Polymers 0.000 description 17
239000008272 agar Substances 0.000 description 17
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 16
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 15
235000013922 glutamic acid Nutrition 0.000 description 15
239000004220 glutamic acid Substances 0.000 description 15
241000894006 Bacteria Species 0.000 description 14
239000003550 marker Substances 0.000 description 14
235000001014 amino acid Nutrition 0.000 description 12
229940024606 amino acid Drugs 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 11
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 10
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 8
235000013477 citrulline Nutrition 0.000 description 8
229960002173 citrulline Drugs 0.000 description 8
239000002609 medium Substances 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000000855 fermentation Methods 0.000 description 6
230000004151 fermentation Effects 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
210000003608 fece Anatomy 0.000 description 5
239000000499 gel Substances 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
240000006024 Lactobacillus plantarum Species 0.000 description 4
235000013965 Lactobacillus plantarum Nutrition 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000002759 chromosomal effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
229940072205 lactobacillus plantarum Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
241000186020 Bifidobacterium dentium Species 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
230000009897 systematic effect Effects 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
208000014644 Brain disease Diseases 0.000 description 2
208000032274 Encephalopathy Diseases 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
229920001503 Glucan Polymers 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
229920002907 Guar gum Polymers 0.000 description 2
206010019663 Hepatic failure Diseases 0.000 description 2
229920001202 Inulin Polymers 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010051606 Necrotising colitis Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
239000001166 ammonium sulphate Substances 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000000665 guar gum Substances 0.000 description 2
229960002154 guar gum Drugs 0.000 description 2
235000010417 guar gum Nutrition 0.000 description 2
230000036737 immune function Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
230000035987 intoxication Effects 0.000 description 2
231100000566 intoxication Toxicity 0.000 description 2
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
229940029339 inulin Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
229940006116 lithium hydroxide Drugs 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
231100000835 liver failure Toxicity 0.000 description 2
208000007903 liver failure Diseases 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
238000010979 pH adjustment Methods 0.000 description 2
230000003405 preventing effect Effects 0.000 description 2
239000006041 probiotic Substances 0.000 description 2
235000018291 probiotics Nutrition 0.000 description 2
230000009183 running Effects 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
241000894007 species Species 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 1
241001655328 Bifidobacteriales Species 0.000 description 1
241000186018 Bifidobacterium adolescentis Species 0.000 description 1
241000186016 Bifidobacterium bifidum Species 0.000 description 1
241001468229 Bifidobacterium thermophilum Species 0.000 description 1
241000459479 Capsula Species 0.000 description 1
208000028399 Critical Illness Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
206010061172 Gastrointestinal injury Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010049416 Short-bowel syndrome Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
OMRWDMWXRWTQIU-YJRXYDGGSA-N Thr-Tyr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N)O OMRWDMWXRWTQIU-YJRXYDGGSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
230000037354 amino acid metabolism Effects 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000000386 athletic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000005008 bacterial sepsis Diseases 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
210000001842 enterocyte Anatomy 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
235000021107 fermented food Nutrition 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000000446 fuel Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
229960000511 lactulose Drugs 0.000 description 1
PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
208000018962 mouth sore Diseases 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
239000006014 omega-3 oil Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
235000016236 parenteral nutrition Nutrition 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
108700022487 rRNA Genes Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
235000014393 valine Nutrition 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Addiction (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)

ZA200505777A 2003-01-31 2004-01-27 New strains of bifidobacterium having the ability to produce glutamine ZA200505777B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0300245A SE526711C2 (sv)	2003-01-31	2003-01-31	Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav

Publications (1)

Publication Number	Publication Date
ZA200505777B true ZA200505777B (en)	2007-12-27

Family

ID=20290264

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200505777A ZA200505777B (en)	2003-01-31	2004-01-27	New strains of bifidobacterium having the ability to produce glutamine

Country Status (16)

Country	Link
US (1)	US7947482B2 (de)
EP (1)	EP1587913B1 (de)
JP (1)	JP4540664B2 (de)
CN (1)	CN100558883C (de)
AT (1)	ATE496115T1 (de)
AU (1)	AU2004208084B2 (de)
BR (1)	BRPI0407176B8 (de)
CA (1)	CA2514659C (de)
DE (1)	DE602004031079D1 (de)
DK (1)	DK1587913T3 (de)
ES (1)	ES2362496T3 (de)
PL (1)	PL212096B1 (de)
RU (1)	RU2352628C2 (de)
SE (1)	SE526711C2 (de)
WO (1)	WO2004067731A1 (de)
ZA (1)	ZA200505777B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2277524T1 (sl)	2005-09-28	2016-02-29	Nordisk Rebalance A/S	Zdravljenje sindroma razdražljivega črevesja z uporabo probiotičnih bakterij in fermentiranih žit kot efektorjev zdravljenja
EP1951272B1 (de) *	2005-10-06	2016-06-15	Probi Ab	Verwendung von lactobacillus zur behandlung von virusinfektionen
WO2012005240A1 (ja) *	2010-07-05	2012-01-12	株式会社明治	腸内腐敗物質の低減作用を有するビフィズス菌
CL2010001124A1 (es)	2010-10-14	2011-01-21	Univ De Concepcion 50% Ma Loreto Ormeno 50%	Alimento funcional probiotico que comprende cepas viables de lactobacillus sp.; uso de dicho alimento funcional para contrarestar los efectos colaterales de la quimioterapia.
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
CN103131647B (zh) *	2011-11-29	2017-06-27	上海上药信谊药厂有限公司	婴儿双歧杆菌及其制剂
CN108771687A (zh)	2012-02-29	2018-11-09	伊西康内外科公司	微生物区系的组合物及与其相关的方法
AR090281A1 (es)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CA2964480A1 (en)	2014-10-31	2016-05-06	Whole Biome Inc.	Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2019046646A1 (en)	2017-08-30	2019-03-07	Whole Biome Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN108330166A (zh) *	2017-09-06	2018-07-27	深圳市百澳飞生物技术有限公司	一种酶制剂的饲用活性评估方法
RU2699967C1 (ru) *	2018-12-25	2019-09-11	Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России)	Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой
US11045507B2 (en)	2019-02-21	2021-06-29	Ewelina Sosnowska-Turek	Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59155321A (ja)	1983-02-25	1984-09-04	Riyoushiyoku Kenkyukai	整腸用製剤
DE3406772A1 (de) *	1984-02-24	1986-03-13	Angelo 8137 Berg Schuler	Diaetetisches mittel zur herabsetzung der harnstoffkonzentration in koerperfluessigkeiten und seine herstellung
SE9002732D0 (sv)	1990-08-24	1990-08-24	Kabivitrum Ab	Product containing growth factor
IT1254210B (it) *	1992-02-10	1995-09-14	Simone Claudio De	Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
JP3623977B2 (ja) *	1993-10-29	2005-02-23	明治乳業株式会社	潰瘍性大腸炎治療剤
JP4852681B2 (ja) *	1996-02-28	2012-01-11	雪印メグミルク株式会社	腸管内細胞溶解活性抑制剤
IT1288119B1 (it)	1996-06-28	1998-09-10	Renata Maria Anna Ve Cavaliere	Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
US6203797B1 (en) *	1998-01-06	2001-03-20	Stephen C. Perry	Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
ID29150A (id) *	1999-01-15	2001-08-02	Entpr Ireland Cs	Penggunaan lactobacillus salivarius
US6468525B1 (en) *	1999-08-10	2002-10-22	Renew Life, Inc.	Probiotic formulation
WO2001083700A2 (en)	2000-05-03	2001-11-08	University Of Maryland, Baltimore	Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
WO2002003879A1 (en) *	2000-07-07	2002-01-17	First Circle Medical, Inc.	Treatment of hiv using hyperthermia
JP2002186422A (ja) *	2000-12-22	2002-07-02	Morinaga Milk Ind Co Ltd	ラクトバシラス・ガッセリ及びビフィドバクテリウム属の菌を含有する非発酵食品
FI109602B (fi)	2001-01-25	2002-09-13	Valio Oy	Probioottiyhdistelmä
PT1359924E (pt)	2001-02-06	2007-12-07	Nestle Sa	Ligação a endotoxina por bactérias de ácido láctico e bifidobactérias
US20030017192A1 (en) *	2001-06-19	2003-01-23	Hanny Kanafani	Process for producing extended shelf-life ready-to-use milk compositions containing probiotics
PE20030284A1 (es) *	2001-07-26	2003-05-01	Alimentary Health Ltd	Cepas de bifidobacterium
JP3364491B2 (ja) *	2002-07-25	2003-01-08	株式会社アトリエ・ド・フロマージュ	ヨーグルトおよびその製造方法

2003
- 2003-01-31 SE SE0300245A patent/SE526711C2/sv not_active IP Right Cessation
2004
- 2004-01-27 EP EP04705562A patent/EP1587913B1/de not_active Expired - Lifetime
- 2004-01-27 AT AT04705562T patent/ATE496115T1/de not_active IP Right Cessation
- 2004-01-27 CA CA2514659A patent/CA2514659C/en not_active Expired - Lifetime
- 2004-01-27 JP JP2006502776A patent/JP4540664B2/ja not_active Expired - Lifetime
- 2004-01-27 ES ES04705562T patent/ES2362496T3/es not_active Expired - Lifetime
- 2004-01-27 US US10/543,604 patent/US7947482B2/en active Active
- 2004-01-27 BR BRPI0407176A patent/BRPI0407176B8/pt not_active IP Right Cessation
- 2004-01-27 AU AU2004208084A patent/AU2004208084B2/en not_active Expired
- 2004-01-27 RU RU2005127331/13A patent/RU2352628C2/ru active
- 2004-01-27 CN CNB2004800088252A patent/CN100558883C/zh not_active Expired - Lifetime
- 2004-01-27 DE DE602004031079T patent/DE602004031079D1/de not_active Expired - Lifetime
- 2004-01-27 WO PCT/SE2004/000098 patent/WO2004067731A1/en active Application Filing
- 2004-01-27 DK DK04705562.9T patent/DK1587913T3/da active
- 2004-01-27 PL PL378435A patent/PL212096B1/pl unknown
- 2004-01-27 ZA ZA200505777A patent/ZA200505777B/en unknown

Also Published As

Publication number	Publication date
BRPI0407176B8 (pt)	2021-05-25
JP2006516405A (ja)	2006-07-06
ATE496115T1 (de)	2011-02-15
RU2005127331A (ru)	2006-01-27
CN100558883C (zh)	2009-11-11
DK1587913T3 (da)	2011-04-11
PL212096B1 (pl)	2012-08-31
AU2004208084A1 (en)	2004-08-12
CA2514659C (en)	2014-07-08
BRPI0407176A (pt)	2006-02-07
BRPI0407176B1 (pt)	2018-05-08
SE0300245D0 (sv)	2003-01-31
WO2004067731A1 (en)	2004-08-12
ES2362496T3 (es)	2011-07-06
JP4540664B2 (ja)	2010-09-08
PL378435A1 (pl)	2006-04-03
EP1587913B1 (de)	2011-01-19
RU2352628C2 (ru)	2009-04-20
EP1587913A1 (de)	2005-10-26
AU2004208084B2 (en)	2008-10-09
CA2514659A1 (en)	2004-08-12
SE0300245L (sv)	2004-08-01
CN1777670A (zh)	2006-05-24
US20060269533A1 (en)	2006-11-30
SE526711C2 (sv)	2005-10-25
US7947482B2 (en)	2011-05-24
DE602004031079D1 (de)	2011-03-03

Publication	Publication Date	Title
EP0760848B1 (de)	1998-02-04	Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
Johansson et al.	1993	Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora
JP4011532B2 (ja)	2007-11-21	ビフィズス菌およびそれを含有する製剤
JP3993168B2 (ja)	2007-10-17	ラクトバシルス・ペントサス株を含む組成物およびそれらの使用
EP2305838B1 (de)	2015-01-28	Bifidobakterien, die folsäure produzieren, nahrungsmittelzusammensetzung und verwendung der bifidobakterien
EP1816190B1 (de)	2013-01-23	Als Probiotikum verwendbares neues Milchsäurebakterium
US20040175372A1 (en)	2004-09-09	Novel lactobacillus reuteri useful as probiotics
EP2828375B1 (de)	2017-11-22	Gaba-erzeugende, aus dem menschlichen magen-darm-trakt stammende kultivierbare bakterie
CN114480229B (zh)	2022-08-09	一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用
CA2514659C (en)	2014-07-08	New strains of bifidobacterium having the ability to produce glutamine
EP1854467B1 (de)	2018-08-15	Immunstimulierende Zusammensetzung
Pieniz et al.	2011	Evaluation of selenite bioremoval from liquid culture by Enterococcus species
CN113832077A (zh)	2021-12-24	鼠李糖乳杆菌及其应用
JP2000256202A (ja)	2000-09-19	新規な生体浄化活性型乳酸菌製剤
CN101328471B (zh)	2010-10-20	青春双歧杆菌grx066及其用途
JP2019218280A (ja)	2019-12-26	入浴用組成物
WO2024055983A1 (zh)	2024-03-21	南瓜籽蛋白组合物和其应用
CN117866831A (zh)	2024-04-12	一种鼠李糖乳酪杆菌及其应用
Dash	2004	Review of scientific evidence for efficacy of Lactobacillus acidophilus DDS-1 as a probiotic strain
CN117866839A (zh)	2024-04-12	一株粪肠球菌xy7及其在制备抗炎和改善痛风食品药品中的应用